Entrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion-positive NSCLC. An updated integrated analysis of entrectinib from the ALKA-372-001, STARTRK-1, and STARTRK-2 trials is presented, with substantially longer follow-up, more patients, and the first description of the median overall survival (OS). An exploratory analysis of entrectinib in ROS1 fusion-positive NSCLC with the central nervous system (CNS)-only progression post-crizotinib is reported.

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC / A. Drilon, C. Chiu, Y. Fan, B.C. Cho, S. Lu, M. Ahn, M.G. Krebs, S.V. Liu, T. John, G.A. Otterson, D.S.W. Tan, T. Patil, R. Dziadziuszko, E. Massarelli, T. Seto, R.C. Doebele, B. Pitcher, N. Kurtsikidze, S. Heinzmann, S. Siena. - In: JTO CLINICAL AND RESEARCH REPORTS. - ISSN 2666-3643. - 3:6(2022), pp. 100332.1-100332.13. [10.1016/j.jtocrr.2022.100332]

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC

S. Siena
Ultimo
2022

Abstract

Entrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion-positive NSCLC. An updated integrated analysis of entrectinib from the ALKA-372-001, STARTRK-1, and STARTRK-2 trials is presented, with substantially longer follow-up, more patients, and the first description of the median overall survival (OS). An exploratory analysis of entrectinib in ROS1 fusion-positive NSCLC with the central nervous system (CNS)-only progression post-crizotinib is reported.
Entrectinib; Intracranial efficacy; NSCLC; ROS1 fusions; Treatment post-crizotinib
Settore MED/06 - Oncologia Medica
Article (author)
File in questo prodotto:
File Dimensione Formato  
2022 Drilon A et al JTO CRR.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 379.3 kB
Formato Adobe PDF
379.3 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/930503
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact